Catalyst Funds Management Pty Ltd
Position in QNCX — Quince Therapeutics, Inc.
CIK 1896150
SYDNEY NSW, C3
Position in QNCX
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$606,000
New position
Shares Held
30,000
first reported quarter
Ownership
0.184%
of shares outstanding
% of Portfolio
0.10%
of 13F equity value
Holder Rank
#17
of 46 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Catalyst Funds Management Pty Ltd holds $22,439,824 across 57 Biotechnology names. QNCX ranks #6 (2.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
66,261 | $6,443,882 | |
| 2 | RPRX |
Royalty Pharma plc
|
79,147 | $3,796,681 | |
| 3 | MRNA |
Moderna, Inc.
|
55,363 | $2,812,440 | |
| 4 | PTCT |
Ptc Therapeutics, Inc.
|
11,200 | $763,056 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
25,031 | $693,358 | |
| 6 | QNCX |
Quince Therapeutics, Inc.
This page
|
30,000 | $606,000 | |
| 7 | ABVX |
Abivax S.A.
|
5,000 | $556,750 | |
| 8 | NKTR |
Nektar Therapeutics
|
6,700 | $482,065 |
All Filings in QNCX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $606,000 | 30,000 | Shares | Sole | 2026-05-11 | |
| No filing history on record for this holder in this stock. | ||||||